Comparing the clinical and economic effects of clinical examination, pulse oximetry, and echocardiography in newborn screening for congenital heart defects: A probabilistic cost-effectiveness model and value of information analysis by Griebsch I et al.
Newcastle University e-prints  
Date deposited:  21 July 2011 
Version of file:  Published  
Peer Review Status: Peer Reviewed 
Citation for published item: 
Griebsch I, Knowles RL, Brown J, Bull C, Wren C, Dezateux CA. Comparing the clinical and economic 
effects of clinical examination, pulse oximetry, and echocardiography in newborn screening for 
congenital heart defects: A probabilistic cost-effectiveness model and value of information analysis. 
International Journal of Technology Assessment in Health Care 2007, 23(2), 192-204.  
Further information on publisher website: 
http://journals.cambridge.org/action/displayJournal?jid=THC 
Publishers copyright statement: 
© Cambridge University Press 2007. This paper is published by Cambridge University Press, and is 
available with access permissions, from the DOI below: 
http://dx.doi.org/10.1017/S0266462307070304 
Always use the definitive version when citing.  
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
• A full bibliographic reference is made to the original source 
• A link is made to the metadata record in Newcastle E-prints 
• The full text is not changed in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
 
 
Robinson Library, Newcastle University, Newcastle upon Tyne, NE1 7RU.   
Tel. 0191 222 6000 
International Journal of Technology Assessment in Health Care, 23:2 (2007), 192–204.
Copyright c© 2007 Cambridge University Press. Printed in the U.S.A.
DOI: 10.1017.S0266462307070304
Comparing the clinical and
economic effects of clinical
examination, pulse oximetry, and
echocardiography in newborn
screening for congenital heart
defects: A probabilistic
cost-effectiveness model and
value of information analysis
Ingolf Griebsch
University of Bristol
Rachel L. Knowles
UCL Institute of Child Health
Jacqueline Brown
University of Bristol
Catherine Bull
Great Ormond Street Hospital for Children
Christopher Wren
Freemann Hospital
Carol A. Dezateux
UCL Institute of Child Health
Objectives: Congenital heart defects (CHD) are an important cause of death and
morbidity in early childhood, but the effectiveness of alternative newborn screening
strategies in preventing the collapse or death—before diagnosis—of infants with treatable
but life-threatening defects is uncertain. We assessed their effectiveness and efficiency to
inform policy and research priorities.
Methods: We compared the effectiveness of clinical examination alone and clinical
examination with either pulse oximetry or screening echocardiography in making a timely
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diagnosis of life-threatening CHD or in diagnosing clinically significant CHD. We
contrasted their cost-effectiveness, using a decision-analytic model based on 100,000 live
births, and assessed future research priorities using value of information analysis.
Results: Clinical examination alone, pulse oximetry, and screening echocardiography
achieved 34.0, 70.6, and 71.3 timely diagnoses per 100,000 live births, respectively. This
finding represents an additional cost per additional timely diagnosis of £4,894 and
£4,496,666 for pulse oximetry and for screening echocardiography. The equivalent costs
for clinically significant CHD are £1,489 and £36,013, respectively. Key determinants of
cost-effectiveness are detection rates and screening test costs. The false-positive rate is
very high with screening echocardiography (5.4 percent), but lower with pulse oximetry
(1.3 percent) or clinical examination alone (.5 percent).
Conclusions: Adding pulse oximetry to clinical examination is likely to be a cost-effective
newborn screening strategy for CHD, but further research is required before this policy
can be recommended. Screening echocardiography is unlikely to be cost-effective, unless
the detection of all clinically significant CHD is considered beneficial and a 5 percent
false-positive rate acceptable.
Keywords: Newborn screening, Congenital heart defects, Cost-effectiveness,
Decision-analytic model, Value of information analysis
Congenital heart defects (CHD) affect approximately up to
9 in every 1,000 live-born infants (24;36), account for 40
percent of deaths due to congenital anomalies (31), and one
in thirteen infant deaths (6). Although the diagnosis of heart
defects may emerge following prenatal or newborn screen-
ing, too often serious defects are only recognized when an
infant develops life-threatening symptoms of cardiovascular
collapse. Timely recognition in the newborn period is vital to
prevent death before definitive management can be initiated
and the morbidity consequent on collapse. Whereas antena-
tal screening programs have the potential to identify CHD
(8), existing evidence suggests these programs have variable
success in recognizing fetuses with serious CHD (1). A UK-
wide study in the mid-1990s found that a fetal diagnosis was
made in only 23 percent of all affected pregnancies and 12
percent of affected live births (11).
Newborn screening by clinical examination is under-
taken in many countries (23). In the United Kingdom, the
cardiovascular component of the routine screening examina-
tion comprises observation for cyanosis, auscultation of the
heart, and palpation of the femoral pulses. The performance
of this program is not routinely evaluated; however, there
is evidence to suggest that the detection rate of the clinical
screening examination is poor (43). A large, prospective UK
study found that the newborn examination detected only 44
percent of CHDs (2).
There is, therefore, likely to be a continued need to
screen infants for serious life-threatening CHDs shortly after
birth. Technological developments make the use of echocar-
diography and pulse oximetry in newborn population screen-
ing feasible, and they now merit further evaluation as new-
born screening tests (4;5;18;25;28;33;34).
The objective of this study was, therefore, to investi-
gate the effectiveness, costs, and cost-effectiveness of adding
pulse oximetry or screening echocardiography to the current
strategy of clinical screening alone to inform future screen-
ing policy and research using a decision-analytic model to
synthesize all available evidence. A subsidiary objective was
to investigate which research priorities would be of great-
est value in reducing uncertainty regarding future newborn
screening policies by using value of information analysis.
METHODS
Objectives of Newborn Screening
The evaluation of newborn screening for CHD presents
several challenges. The general term “congenital heart de-
fects” comprises a variety of malformations with varying
prevalence, clinical features, natural history, management
and hence anticipated benefit from screening. Furthermore,
screening echocardiography when used in early life may re-
veal some structural heart malformations (e.g., ventricular
septal defects [VSDs]) that are of no functional or clini-
cal consequence and remain undiagnosed or resolve sponta-
neously. Clarity regarding the precise objectives of newborn
screening is required if optimal screening strategies are to be
selected and evaluated. We classified CHD into three groups
according to the anticipated benefit from newborn screen-
ing (Box 1). There is increasing evidence to suggest that
preoperative collapse is associated with higher postopera-
tive mortality and morbidity and later neurological seque-
lae (7;10;13;27), but data have not been related to mode of
detection. We, therefore, selected timely diagnosis of “life-
threatening” CHD (Box 1) as the primary outcome of the
model, defined as a diagnosis made preoperatively before
collapse or death occurs. This approach assumes definitive
management is initiated at the time of diagnosis, and is effec-
tive in preventing pre-operative collapse. For instance, man-
agement might start with prostaglandin infusion and proceed
with surgery. The secondary outcome was the diagnosis of
“clinically significant” defects, along with the timely diag-
nosis of defects included in the primary outcome.
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Box 1. Classification of congenital heart defects
Groups of congenital
heart defects Description Example of defects included in groups
Group 1: Life-threatening Structural cardiac malformations in which
collapse is likely. Prevention of collapse before
definitive management (surgery) is likely to
decrease mortality and long-term disability
Transposition of the great arteries (TGA)
Severe coarctation of the aorta/interruption of the
aortic arch (COA/IAA)
Aortic stenosis (AS)
Hypoplastic left heart/mitral atresia (HLH/MA)
Total anomalous pulmonary venous connection
(TAPVC)
Pulmonary valve atresia (PA)
Group 2: Clinically
significant
Structural cardiac malformations with minimal
probability of collapse or with no feasible or
effective prevention of collapse
Tetralogy of Fallot (TOF)
Complete atrioventricular septal defect (CASD)
Truncus arteriosus (TA), ventricular septal defect
(VSD)
Atrial septal defect (ASD)
Large persistent ductus arteriosus (not preterm)
(PDA)
Group 3: Clinically
nonsignificant
Anatomically defined cardiac malformations of
no functional clinical significance
Spontaneously resolving or small ventricular
septal defects and atrial septal defects
Small persistent ductus arteriosus (not preterm)
Very mild pulmonary stenosis
No single clinical screening test will identify all
defects—for instance, not all are associated with a murmur.
Pulse oximetry will not detect noncyanotic defects. Although
nonspecialist ultrasonographers located near obstetric units
might recognize that the heart they were examining was not
normal, they could rarely provide a confident diagnosis. For
diagnostic echocardiography and any subsequent treatment,
the baby must travel to a specialist center. As well as re-
ferrals that are clearly appropriate, screening echocardiogra-
phers might send babies with malformations that are of no
functional consequence or that a specialist could be confident
would resolve spontaneously.
The Decision Problem
We identified three potential screening strategies: (i) clinical
examination alone, (ii) pulse oximetry in addition to clinical
examination, and (iii) screening echocardiography in addi-
tion to clinical examination. With clinical examination alone,
the test is positive if the infant has visible cyanosis, a car-
diac murmur, or diminished femoral pulses. Pulse oximetry
screening involves measurement of post-ductal oxygen satu-
ration as an adjunct to clinical examination; a positive result is
defined by arterial saturation of less than 95 percent on two
consecutive occasions (34), with or without positive find-
ings on clinical examination. Screening echocardiography
involves an echocardiogram performed by a nonspecialist in
addition to clinical examination; a positive screening result is
defined by an abnormal appearance on four chamber, outlet,
or arch views with or without positive findings on clinical
examination. A “no screening” strategy was not considered
to be a practical or ethical option. We assumed newborn
screening would take place at 24 hours of age.
Development of Decision-Analytic Model
We developed a decision model to simulate the sequence of
events experienced by 100,000 live-born infants up to the
point of diagnosis. Figure 1 presents a simplified version of
this model. Infants with undiagnosed life-threatening CHDs
are assumed to be at risk of cardiovascular collapse and
death anytime before diagnostic echocardiography by a spe-
cialist is performed. An affected infant might collapse after
either a positive or a false-negative screening test, if they
were not screened. As data were not available for infants
who missed screening, we assumed they had a similar risk of
cardiovascular collapse to infants with false-negative screen-
ing results. Infants with life-threatening CHDs who screen
positive and do not collapse before diagnostic echocardiog-
raphy are considered to have received a “timely diagnosis”
(primary outcome). We assumed all pathway probabilities
varied according to specific CHD but were constant across
screening strategies, with the exception of the detection and
false-positive rates, which varied by both these factors.
Data Used in the Model
Data for prevalence at screen and birth, test performance, and
risk of cardiovascular collapse were derived from a system-
atic review (Medline [1966 onward], Embase [1980 onward],
Cinahl [1982 onward]) and from a population-based register
of CHDs in the Northern Region of England (43). No ran-
domized trials comparing the different screening strategies
were found. Hence, published and unpublished observational
data were used in the model. Where data were not available
from these sources, input parameters were obtained as sub-
jective probabilities (26) from two or three pediatric cardiolo-
gists who provided individual estimates that were negotiated
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until consensus was reached (17). Resulting probability
ranges were translated into full probability distributions (38).
Prevalence of Unrecognized Congenital
Heart Defects at the Point of Screening
The Northern Region data set (43) was the source of defect-
specific prevalence estimates with a population-based de-
nominator and follow-up of over 15 years, including post-
mortem diagnoses, to achieve complete case ascertainment
with adjustment for the number of additional cases detected
between 1 and 16 years (24;42). On the basis of Hoff-
man and Kaplan (24), we increased the baseline prevalence
of ventricular septal defects (VSDs) by 95 percent to es-
timate those detected by screening echocardiography, and
the prevalence of persistent ductus arteriosus, atrial septal
defects, and pulmonary stenosis similarly by 61 percent.
We assumed that, at the point of newborn screening, the
prevalence of unrecognized CHDs would depend on the pro-
portion detected by antenatal screening, or by the presence
of readily recognizable extracardiac defects associated with
CHDs, such as Down’s syndrome, lethal trisomies (13 or
18), gastroschisis, exomphalos or through symptomatic pre-
sentation before screening. Such infants require specialist
cardiac assessment and were excluded from routine screen-
ing in the model. We used defect-specific antenatal detec-
tion and termination of pregnancy rates from the Northern
Region (43) in the base case and explored the effect of us-
ing average national UK antenatal detection rates (11) and
of possible future improvements in fetal ultrasound screen-
ing in sensitivity analyses. Northern Region data were used
to calculate the number of children with extracardiac de-
fects, supplemented with data from a study of gastrointesti-
nal defects (41), Eurocat surveillance data (19), and the UK
Down’s Syndrome Register (3). We used Northern Region
data to identify the number of infants with unrecognized
CHDs at 24 and 48 hours of age (Table 1 and Supplemental
Table 1 [http://www.journals.cambridge.org/jid thc]). Fig-
ure 2 shows the decision model used to calculate the preva-
lence of CHDs at the point of screening.
Test Performance
The detection rate for specific CHDs and the false-positive
rate were derived from the Northern Region data set and from
a population-based study of newborn screening (21), respec-
tively. Estimates of test performance for pulse oximetry were
taken from published studies (34), supplemented by expert
opinion. As the only randomized trial identified was small
and excluded many subjects before randomization (37), es-
timates of test performance for screening echocardiography
were supplemented by expert opinion (Table 1 and Supple-
mental Table 2 [http://www.journals.cambridge.org/jid thc]).
Other Probabilities
The probability of being screened (coverage), was esti-
mated as 93 percent for clinical examination (21), 93 per-
cent for pulse oximetry (34), and 91 percent for screen-
ing echocardiography (37). We derived probabilities of di-
agnosis without cardiovascular collapse in an affected in-
fant given a negative screening result or no screening be-
tween 1 and 16 years from Wren and O’Sullivan (42) and
Wren et al. (43). Expert opinion was used for all remain-
ing pathway probabilities (Table 1 and Supplemental Table
2 [http://www.journals.cambridge.org/jid thc]]).
Costs
Costs were estimated from the UK health service perspective
and included screening and diagnostic tests, management of
collapsed infants, staff, equipment, consumables, and over-
head (see Table 2). Costs were adjusted to 2000/2001 prices
and were not discounted as the model considers only the first
year of life. Costs were entered as pounds sterling, with £1
sterling equivalent to US $1.872 or €1.478 (as at 13 Septem-
ber 2006).
Evaluation of Cost-Effectiveness
The model was programmed and analyzed in Microsoft Ex-
cel 2000. The model was based on 100,000 live-born infants
entering the screening pathway, and the “base case” anal-
ysis assumed that the antenatal detection rate for specific
heart defects from the Northern Region applied, newborn
screening was performed at 24 hours of age and the primary
outcome was used. For each screening strategy, we calcu-
lated the overall detection rate, the number of infants with
true-positive and false-positive screening results, the positive
predictive value, and the false-positive rate for the primary
and secondary outcomes (26). For each screening strategy,
incremental cost-effectiveness ratios (ICERs) were presented
as the additional cost per additional timely diagnosis com-
pared with the next most effective strategy.
Assessing Uncertainty
Sensitivity analyses were undertaken to examine the robust-
ness of the base case analysis to alternative assumptions.
Within the model, we explored the implications of improved
coverage for screening echocardiography, a detection rate of
100 percent for screening echocardiography, differing ante-
natal detection rates, immediate access to diagnostic test-
ing after a presumptive positive screen, and varying age at
screening (birth or 48 hours). To derive a distribution of
expected costs and outcomes (9), we assigned probability
distributions to input parameters and conducted probabilistic
sensitivity analyses (i.e., Monte Carlo, 10,000 iterations; see
Tables 1 and 2 and Supplemental Table 1). The probability
of a strategy being cost-effective using a range of different
thresholds for cost-effectiveness was estimated using the net
benefit approach (39) and displayed using cost-effectiveness
acceptability curves (20).
Value of Information Analysis
Because a preference for a particular screening strategy is
subject to various uncertainties in the input parameters of
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Table 1. Source of Data for the Model
Data Source References and notes
Clinical Data (see also Supplemental Tables 1-2)∗
Defect-specific prevalence estimates of
CHDs at newborn screening and at birth
Systematic review; Population-based
register of CHDs in the Northern Region
of England
Prevalence of unrecognized CHDs at 24
and 48 hours of age estimated from
Northern Region data (43); adjustment
for additional cases detected between 1
and 16 years (24;42); additional cases
detected by screening echocardiography;
baseline prevalence of ventricular septal
defects increased by 95%; prevalence of
persistent ductus arteriosus, atrial septal
defects, and pulmonary stenosis
similarly by 61% (24;42)
Screening test performance Systematic review; Subjective probabilities Clinical examination: Northern Region
data (43)
Pulse oximetry: randomized trial (34)
supplemented by expert opinion
Screening echocardiography: randomized
trial (37) supplemented by expert
opinion
Defect-specific risk of cardiovascular
collapse
Subjective probabilities (26) Two to three pediatric cardiologists
provided individual estimates that were
negotiated until consensus was reached
(17)
Probability of diagnosis without collapse:
affected infants
Northern Region data Estimated for an affected infant given a
negative screening result or no screening
(24;42)
Infants requiring specialist assessment &
excluded from routine screening:
Extracardiac defects symptomatic
presentation Antenatal screening
Northern Region data; Systematic review
Eurocat surveillance; UK Down’s
Syndrome Register
Northern Region data (43) for the number
of affected children with symptomatic
presentation before screening or with
extracardiac defects (Down’s syndrome
and lethal trisomies); estimates
supplemented by a study of
gastrointestinal defects (41) Eurocat
surveillance data (Table B3 1996–99;
www.biomedicalweb.biz/eurocat) and
UK Down’s Syndrome Register (3);
base case: defect-specific antenatal
detection and termination of pregnancy
rates from Northern Region(43);
sensitivity analyses: national UK
antenatal detection rates (11) and
possible future improvements in fetal
ultrasound screening
False-positive rate Systematic review Population-based study of newborn
screening (21)
Screening coverage Systematic review 93% for clinical examination (21); 93% for
pulse oximetry (37); 91% for screening
echocardiography (expert opinion)
∗http://www.journals.cambridge.org/jid thc
CHDs, congenital heart defects.
the model, we used value of information analysis (12;16) to
assess the value of perfect information (EVPI) and the partial
expected value of information (EVPPI) for groups of model
input parameters. This analysis assumes the maximum value
placed on research to eliminate uncertainty is equivalent to
the opportunity cost of making the wrong decision under
current uncertainty and can be used to identify those param-
eters for which further research would be most valuable. The
population EVPI (i.e., EVPI for the whole current and future
population of interest; in this case, all infants undergoing
newborn screening) was calculated by multiplying the “per
person” EVPI (in this model per 100,000 persons) by the
number of newborns (I ) in each time period (t) discounted
at rate r over the assumed lifetime of the screening techno-
logy (T ):
Population EVPI = EVPI ·
T∑
t=1
I
t
(1+ r)t
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Table 2. Data Used to Calculate Unit Costs (2000/2001 Prices)
Base case value Probability distributiona Source
Time required to perform screen and diagnostic assessment
Duration of clinical examination 2.0 minutesb Gamma (12.84, .16) Observations at University College
Hospital Trust
Duration of pulse oximetry 2.0 minutes Gamma (12.84, .16) Clinical expert view
Duration of screening echocardiography 10.0 minutes Gamma (12.76, .78) Observations at Great Ormond Street
Hospital
Duration of diagnostic echocardiography 30.0 minutes Gamma (12.76, 2.35) Clinical expert view
Staff unit costs (per minute)
Senior house officer £.58 n/a Unit costs of Health and Social Care 2001
(30)c
Radiographer (Senior 1) £.65 n/a Unit costs of Health and Social Care 2001
(30)c
Consultant £2.01 n/a Unit costs of Health and Social Care 2001
(30)c
Equipment costs per screend
Pulse oximetry machine costs £.48 Uniform (.31, .64) Manufacturers and Hospital Episode
Statistics (Department of Health)
Echocardiography machine costs £23.97 Uniform (13.85, 34.09) Manufacturers and Hospital Episode
Statistics (Department of Health)
Sum screening unit costs
Clinical examination alone £1.17 n/a
Pulse oximetry £2.82 n/a
Screening echocardiography £31.67 n/a
Cost associated with management of
collapsed infants
Cost for treating collapsed infants £3,215 Uniform (1,429, 7,438) Roberts et al., 1998 (35)
Cost of postmortem examination £942 Uniform (471, 1,413) Roberts et al., 1998 (35)
Cost of ambulance transport £238 Uniform (119, 357) Roberts et al., 1998 (35)
a Parameter for probability distributions: alpha, beta for Gamma distribution; minimum, maximum for Uniform distribution.
b SD= .56, n= 12.
c Uprated by 40% to take overheads into account.
d Low cost estimates assumed a high delivery rate (75th percentile of the national deliveries) and a low cost of equipment, whereas high cost estimates
assumed a low delivery rate (25th percentile of the national deliveries) and high equipment cost. The midpoint was used in base case analysis.
An effective lifetime of the screening technology of 5
years was assumed, and the number of newborns (549,566)
per year over this 5-year period was based on the number of
hospital deliveries in England during the year 2000/2001. A
discount rate of 6 percent per annum was applied.
RESULTS
Overall Screening Test Performance
Table 3 details the clinical results of the model analysis.
Based on the base case decision model for 100,000 infants,
167 are predicted to have life-threatening CHDs, of whom
121 will remain unrecognized at 24 hours of age (see Table 2).
A further 543 infants are predicted to have clinically sig-
nificant CHDs, of whom 425 will remain unrecognized at
24 hours. The percentage of live-born infants with positive
screening results is highest for screening echocardiography
(5.4 percent; 4,940) and lowest for clinical examination alone
(.5 percent; 499).
Clinical examination alone results in 34.0 timely diag-
noses per 100,000 live births, compared with 70.6 for pulse
oximetry and 71.3 for screening echocardiography. Screen-
ing echocardiography and pulse oximetry detect a similar
proportion of infants with life-threatening CHDs (69 per-
cent and 68 percent, respectively), twice the proportion de-
tected by clinical examination (32 percent). Using the sec-
ondary outcome (all clinically significant and life-threatening
CHDs combined), the detection rates for pulse oximetry
and screening echocardiography are 62 percent and 50 per-
cent, respectively, compared with 32 percent for clinical
examination.
Screening echocardiography is associated with the high-
est false-positive rate (5.4 percent; 4857), which includes
3,644 infants with clinically nonsignificant CHDs. This num-
ber is substantially lower for clinical examination (.5 percent,
460 infants) and pulse oximetry (1.3 percent, 1,168 infants).
The predictive value of a positive screening test for life-
threatening CHDs is 7.8 percent for clinical examination,
6.6 percent for pulse oximetry, and 1.7 percent for screening
echocardiography.
Cost-Effectiveness
Total costs are lowest for clinical examination (£296,891
per 100,000 live births) and highest for screening
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Table 3. Estimated Performance per 100,000 Live Birthsa of Alternative Screening Strategies to Detect Congenital
Heart Defects (CHD): Base Case Analysis
Strategy
Clinical examination Pulse oximetry Screening
(CE) alone (PO) echocardiography (SE)
Expected number of life-threatening CHD
At birth (n) 167 167 167
At screen (n) 121 121 121
Expected no. of other CHDs
At birth (n) 543 543 543
At screen (n) 425 425 425
CHDb only detected by echo (n) n/a n/a 4,218
No. screened 92,728 92,728 90,734
Positive screening result: 499 (.5%) 1,250 (1.3%) 4,940 (5.4%)
n (as % of no. screened)
True positives 39 82 83
False positives 460 1,168 4,857
Negative screening result 92,230 91,478 85,794
False negatives 73 30 27
True negatives 92,156 91,448 85,767
No. of cases with timely diagnosisc 34 71 71
due to newborn screen
Detection rate (%) 32.3% 67.9% 68.5%
Positive predictive value 7.8% 6.6% 1.7%
False-positive rate .5% 1.3% 5.4%
a Rounded to the nearest whole number, unless otherwise stated.
b Anatomically defined cardiac malformations of no functional clinical significance, for example, tiny ventricular septal defects.
c Affected infants diagnosed before collapse or death occurs.
echocardiography (Table 4). The cost per additional timely
diagnosis is £4,894 for pulse oximetry compared with clin-
ical examination, and £4,496,666 for screening echocardio-
graphy compared with pulse oximetry. Using the secondary
outcome, the cost per additional diagnosis falls to £1,489 for
pulse oximetry and £36,013 for screening echocardiography.
Sensitivity Analyses
These results are sensitive to detection rates for screening
echocardiography and age at screening, but robust to assump-
tions about antenatal detection rates using published ranges,
availability of diagnostic echocardiography and coverage of
screening echocardiography. If the detection rate for screen-
Table 4. Results of the Economic Analyses per 100,000 Live Births (2000/2001 Prices)
Total No. of timely Incremental cost-effectiveness
costs (£) diagnoses ratios (£)
Primary outcome: Timely diagnosis of life-threatening congenital heart defects (CHD)
Clinical examination alone 296,891 34.0 —
Pulse oximetry 476,193 70.6 4,894
Screening echocardiography 3,540,388 71.3 4,496,666
Secondary outcome: Primary outcome AND diagnosis of clinically significant CHD
Clinical examination alone 297,627 222.4 —
Pulse oximetry 476,016 342.2 1,489
Screening echocardiography 3,457,233 427.4 36,013
ing echocardiography is assumed to be 100 percent, the cost
per timely diagnosis falls to £126,606 and £22,291 for the
primary and secondary outcomes, respectively. Similarly, if
newborn screening were to be performed immediately after
birth, the cost per timely diagnosis for pulse oximetry falls
to £3,406 and to £1,176 for the secondary outcome, whereas
screening echocardiography becomes more costly and less
effective than pulse oximetry. Conversely, if screening were
to be undertaken at 48 hours, the cost per timely diagno-
sis rises to £8,195 and £1,928,151 for pulse oximetry and
screening echocardiography, respectively, for screening at
48 hours of age, and for the secondary outcome to £2,183
and £46,010, respectively. If antenatal detection rates rise due
to future improvements in fetal ultrasound, then the cost of
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Figure 3. Cost-effectiveness acceptability curves for base case analysis and primary outcome. Curve shows the probability
that a screening modality is cost-effective for a range of decision-makers’ maximum willingness to pay per timely diagnosis of
life-threatening heart defects.
detecting additional cases with newborn screening increases
but only begins to rise steeply once antenatal detection rates
of 85–90 percent are achieved (data not shown).
Probabilistic Sensitivity Analysis
Uncertainty around these estimates is represented by cost-
effectiveness acceptability curves, which show the probabil-
ity that one of the three screening combinations/options is
cost-effective compared with a maximum willingness to pay
that decision makers might have for these health outcomes
(Figures 3 and 4 for the primary and secondary outcome, re-
spectively). For example, the probability that pulse oximetry
is cost-effective is .53 if the willingness to pay per timely di-
agnosis of life-threatening CHDs is £5,000. This probability
increases to over .90 if decision makers are willing to pay
between £10,000 and £100,000 for a timely diagnosis (Fig-
ure 3). The cost-effectiveness acceptability for the secondary
outcome is shown in Figure 4, indicating that the probability
of screening echocardiography is over .50 at a willingness
to pay of around £50,000 per timely diagnosis of clinically
significant CHDs.
Value of Information Analysis
The maximum monetary value of further research for an
arbitrary cost-effectiveness threshold of £50,000 per timely
diagnosis is £744,000 and £14,450,000 for the primary and
secondary outcomes, respectively. At this threshold, key de-
terminants of cost-effectiveness with a maximum value of
future research for primary and secondary outcome, res-
pectively, are detection rates of pulse oximetry (£557,000;
£11,320,000), screening echocardiography (£0; £4,958,000),
and screening test (£275,000; £5,285,000) costs.
DISCUSSION
Our findings suggest that the addition of pulse oximetry to
clinical examination is likely to detect twice as many life-
threatening CHDs in affected infants before death or col-
lapse occurs. This strategy appears cost-effective but further
research is required before this change should be recom-
mended as policy.
Although encouraging, this study alone is not sufficient
to permit recommendation of adding pulse oximetry to a
newborn screening checklist immediately. First, our value
of information analysis supports targeting future research
at reducing uncertainty around detection and false-positive
rates for pulse oximetry, reflecting the fact that the few ob-
servational studies reporting experience with this test have
been based on small samples (4;5;18;25;28;33;34). Second,
protocols to specify the measurement of oxygen saturation
(including operator, algorithm, and number and timing of
measurements) and the proper investigation of positive
screening results, considering the benefit of identifying respi-
ratory and neurological abnormalities also, are essential be-
fore this screening strategy could be adopted. Existing studies
of the feasibility and performance of pulse oximetry in the de-
tection of cyanotic CHD have reported occasions when cyan-
otic life-threatening defects have been missed (34). Larger
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Figure 4. Cost-effectiveness acceptability curves for base case analysis and secondary outcome. Curve shows the probability
that a screening modality is cost-effective for a range of decision-makers’ maximum willingness to pay per timely diagnosis of
life-threatening heart defects and diagnosis of clinically significant heart defects.
studies are needed to estimate the detection rate of pulse
oximetry more precisely. Similarly, surveillance of screen-
negative populations is needed to define the negative pre-
dictive value of pulse oximetry, that is, to estimate the risk
of falsely reassuring parents that their child does not have a
CHD when the defect is acyanotic.
Although screening echocardiography and pulse oxime-
try may lead to a similar proportion of timely diagnoses of
life-threatening CHDs, screening echocardiography is more
costly in financial terms and in consequences for families of
infants with false-positive diagnoses, which include a high
number of those with clinically nonsignificant CHDs. This
remains true for the secondary outcome, although in this
case, screening echocardiography and pulse oximetry are
more differentiated and screening echocardiography appears
more attractive in terms of cost-effectiveness. In practice, it
would be difficult to disregard information about clinically
nonsignificant CHDs, although their detection is of arguable
benefit to the child. Because newborn screening for CHD
should be considered in conjunction with the total antenatal
and newborn experience of mothers and infants, the additive
effects of false-positive diagnoses becomes highly relevant
(29).
The limitations of our study reflect limitations in primary
data sources as well as methodological limitations in this
field. There was a paucity of studies comparing longer-term
outcomes between screened and unscreened populations and
model parameters were based on evidence from observa-
tional studies and, extensively, on expert opinion. We could
not quantify the disbenefits associated with false-positive
screening results and the application of generic measures
that potentially could capture these disbenefits, for example
quality-adjusted life-years, was limited by the lack of out-
come data (27) and the problems of using existing generic
measures for health-related quality of life in newborn in-
fants and young children (22;32;40). Sensitivity analyses
demonstrated that relative cost-effectiveness is determined
mainly by the choice of outcome measure (life-threatening
or all CHD diagnoses) and the value society attaches to these
outcomes. By including value of information analysis, we
were able to identify parameters for which more precise es-
timates would reduce the uncertainty surrounding the choice
of screening strategy and indicate where further research
would be of most value. The value of information approach
has been highlighted recently as a potential aid for setting
research priorities in the context of health technology assess-
ment (12;14–16).
A further limitation in the model is the lacking informa-
tion on the dependence of age at screening and test perfor-
mance. When different ages at screening were investigated
in the model, we assumed that the mean detection rate and its
associated uncertainty remained the same. Further research
is needed to determine whether such a dependency exists in
clinical practice and, if so, then the optimal age at screening
needs to be determined.
Clearly, strategies for the early detection of CHDs re-
quire an integrated approach across antenatal and newborn
screening programs and postnatal referral protocols. Antena-
tal diagnosis allows delivery in specialist centers with prompt
intervention available. Our model would accommodate
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future updating with population-based antenatal screen-
ing data. Although the timely management of infants who
“screen positive” does not differ between screening strate-
gies, it is a crucial practical consideration. Telemedicine
transmission of scanned images for specialist evaluation
might bring forward effective treatment for some conditions,
but others need urgent surgical intervention.
POLICY IMPLICATIONS
The policy implications resulting from our analysis are clear.
This analysis suggests that there is scope to improve the
effectiveness of newborn screening policies for CHDs by
implementing a combined strategy of pulse oximetry and
clinical examination. Before implementing this strategy in
clinical practice, the development of protocols to specify the
measurement of oxygen saturation and the proper investiga-
tion of positive screening results, considering the benefit of
identifying respiratory and neurological abnormalities also,
are essential.
Further research is about to be commissioned by the
National Health Service Research and Development Health
Technology Assesssment Programme as a result of our study
and will be aimed at reducing uncertainties surrounding the
use of pulse oximetry as a population screening strategy
(see www.ncchta.org for more information). This research is
important in view of the significant contribution of CHD to
infant mortality in industrialized countries (36).
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